Key result
Plasma MR-proADM at ICU admission was a significant predictor of intra-hospital mortality (OR 1.27; 95% CI 1.03-1.55; p=0.022), with prognostic accuracy comparable to APACHEII and SAPSII scores.
Why the study?
Does plasma MR-proADM at ICU admission predict intra-hospital mortality in non-selected critically ill patients?
Population
126 consecutive non-selected patients admitted to an intensive care unit (ICU)
Comparison
Plasma mid-regional pro-adrenomedullin measured… vs Acute Physiology and Chronic Health Evaluation…
Design
Cohort
Follow-up
Intra-hospital
Authors
Loading...
May aid ICU risk stratification; leaves open incremental value over APACHEII/SAPSII in prospective studies.
Observational (n=126)
Does plasma MR-proADM at ICU admission predict intra-hospital mortality in non-selected critically ill patients?
Odds Ratio: 1.27 (95% CI 1.03–1.55)
p-value: p=0.022
MR-proADM measured at ICU admission is a reliable predictor of intra-hospital mortality and length of stay, performing comparably to established clinical scores like APACHEII and SAPSII.
Bellia et al. (2018) conducted an observational in Critically ill patients admitted to an intensive care unit (n=126). Plasma mid-regional pro-adrenomedullin (MR-proADM) vs. APACHEII and SAPSII scores was evaluated on Intra-hospital mortality (OR 1.27, 95% CI 1.03-1.55, p=0.022). Plasma MR-proADM at ICU admission was a significant predictor of intra-hospital mortality (OR 1.27; 95% CI 1.03-1.55; p=0.022), with prognostic accuracy comparable to APACHEII and SAPSII scores.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: